Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Daily News

FDA Proposes Ban on Menthol Cigarettes and Flavored Cigars

Michael O'Riordan

April 28, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Daily News

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

Michael O'Riordan

August 17, 2021

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Daily News

FDA Is Surveilling Heparin but Believes Defective Quality Unlikely

Yael L. Maxwell

December 06, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

News Daily News

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Caitlin E. Cox

September 08, 2016

Advertisement

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

New Faces, New Formats, New Tech: What to Expect From TCT 2022

FDA Proposes Ban on Menthol Cigarettes and Flavored Cigars

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Could an App Replace Statin Prescribing by Doctors?

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

FDA Is Surveilling Heparin but Believes Defective Quality Unlikely

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content